Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo ...
The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...
Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...
The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.
(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer.
Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...
Roche received expanded approval from the Food and Drug Administration for a test to diagnose breast cancer. The pharmaceutical company said Monday that the FDA approved the PATHWAY HER2 (4B5) test ...
After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
Khaleej Times on MSN
US FDA approves AstraZeneca, Daiichi's breast cancer drug as first-line treatment
The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback